Bezlotoxumab is a human monoclonal antitoxin antibody that binds with high affinity to Clostridium difficile toxin B and neutralises its activity. It received a marketing authorisation in January 2017 and is expected to be launched in June 2017. Bezlotoxumab is licensed for preventing future episodes of diarrhoea in people who are taking antibiotics to treat their C difficile infection and who are at high risk of the infection coming back. It is administered as a single one-off intravenous infusion during a course of antibacterial therapy for C difficile infection.